796073-68-2

Basic information

• Product Name: N^2'-deacetyl-N^2'-[4-methyl-4-(methyldithio)-1-oxopentyl]maytansine
• CAS NO: 796073-68-2
• Molecular Weight: 826.473
• Mol File: 796073-68-2.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: N^2'-deacetyl-N^2'-[4-methyl-4-(methyldithio)-1-oxopentyl]maytansine(CAS DataBase Reference)
• NIST Chemistry Reference: N^2'-deacetyl-N^2'-[4-methyl-4-(methyldithio)-1-oxopentyl]maytansine(796073-68-2)
• EPA Substance Registry System: N^2'-deacetyl-N^2'-[4-methyl-4-(methyldithio)-1-oxopentyl]maytansine(796073-68-2)

Safety Data

• Hazardous Substances Data: 796073-68-2(Hazardous Substances Data)

Upstream product

• 796073-57-9 N-methyl-N-[4-methyl-(4-methyldithio)-1-oxopentyl]-L-alanine 
• 57103-68-1 maytansinol 
• 131237-84-8 4-mercapto-4-methylvaleronitrile 
• 66584-72-3 ansamitocin P-3 
• 796073-55-7 N-methyl-N-[4-methyl-(4-methyldithio)-1-oxopropyl]-L-alanine 
• 77668-69-0 (1⁴S,1⁶S,3²R,3³R,2R,4S,10E,12E,14R)-8⁶-chloro-1⁴-hydroxy-8⁵,14-dimethoxy-3³,2,7,10-tetramethyl-1²,6-dioxo-7-aza-1(6,4)-oxazinana-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-4-yl methyl-L-alaninate 
• 1452404-52-2 Fmoc-N-Me-L-Ala-maytansinol 
• 140231-31-8 4-mercapto-4-dimethylpentanoic acid 
• 796073-56-8 2,5-dioxopyrrolidin-1-yl 4-methyl-4-(methyldisulfanyl)pentanoate 

Downstream Products

• 796073-69-3 N^2′-deacetyl-N^2′-(4-mercapto-4-methyl-1-oxopentyl)maytansine 

Relevant articles and documents

Uses of immunoconjugates targeting CD138

Disclosed is a method and composition for treating a disease associated with target cells expressing CD138 in a multiple dose regimen. An immunoconjugate comprising an engineered targeting antibody targeting CD138 expressing cells and an effector molecule is administered in a multiple dose regimen. The multiple dose regimen comprises at least two doses and the aggregate dose administered within an active treatment cycle is an aggregate maximum tolerable dose (AMTD) or a fraction of the AMTD. The AMTD and/or said fraction exceeds the dose resulting in dose limiting toxicity (DLT) and/or exceeds the maximum tolerable dose (MTD) when the immunoconjugate is administered as a single dose, including as part of a multiple single dose regimen within said active treatment cycle.

Ado-trastuzumab emtansine (T-DM1): An antibody-drug conjugate (ADC) for HER2-positive breast cancer

Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that combines the antitumor properties of the humanized anti-human epidermal growth factor receptor 2 (HER2) antibody, trastuzumab, with the maytansinoid, DM1, a potent microtubule-disrupting agent, joined by a stable linker. Upon binding to HER2, the conjugate is internalized via receptor-mediated endocytosis, and an active derivative of DM1 is subsequently released by proteolytic degradation of the antibody moiety within the lysosome. Initial clinical evaluation led to a phase III trial in advanced HER2-positive breast cancer patients who had relapsed after prior treatment with trastuzumab and a taxane, which showed that T-DM1 significantly prolonged progression-free and overall survival with less toxicity than lapatinib plus capecitabine. In 2013, T-DM1 received FDA approval for the treatment of patients with HER2-positive metastatic breast cancer who had previously received trastuzumab and a taxane, separately or in combination, the first ADC to receive full approval based on a randomized study.

Method for the preparation of maytansinoid esters

Improved processes for the preparation and purification of maytansinoid esters, especially thiol and disulfide-containing maytansinoids are described. In one aspect the process comprises a process of making a maytansinoid ester comprising forming an anion of maytansinol or a maytansinoid bearing a free C-3 hydroxyl moiety and reacting the anion with an activated carboxyl compound to thereby produce the maytansinoid ester.